Changes in Hong Kong stocks | Ruibo Bio-B (06938) rose nearly 6% in early trading and has submitted a phase I clinical trial application for the dual-target siRNA drug SR122 in the EU

The Zhitong Finance App learned that Ruibo Biotech B (06938) rose nearly 6% in early trading. As of press release, it had risen 3.18% to HK$44.76, with a turnover of HK$3.3618 million.

According to the news, on November 10, Ruibo Bio-B announced that the company has submitted a Phase I clinical trial application (CTA) in the European Union for the dual-target siRNA drug SR122 (a type of GalNAC-conjugated siRNA therapy for the treatment of dyslipidemia including severe hypertriglyceridemia (SHTG) and mixed dyslipidemia).

The submission of this CTA marks a further refinement of the company's lipid pipeline strategy and is also an important step in consolidating its leading position in the field of dyslipidemia. The company is also continuing to advance phase II clinical research on its core lipid-lowering product RBD5044 (siRNA therapy targeting APOC3, which is the second most advanced in global clinical development) in Europe and China.

This phase I clinical trial is a randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR122 subcutaneously injected in healthy subjects. The study will be the first clinical evaluation of the dual-target drug SR122 in humans and will generate key data to support its further development.